1. Stilbenoid derivatives as potent inhibitors of HIF-1α-centric cancer metabolism under hypoxia
- Author
-
Tae-Hee Han, Joohan Lee, Dipesh S. Harmalkar, Hyeseul Kang, Guanghai Jin, Min Kyung Park, Minkyoung Kim, Hyun-A Yang, Jinsu Kim, Su Jeong Kwon, Tae-Su Han, Yongseok Choi, Misun Won, Hyun Seung Ban, and Kyeong Lee
- Subjects
Stilbenoid analogs ,anticancer activity ,hypoxic cancer ,HIF-1α ,cancer metabolism ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Hypoxia-inducible factor (HIF)-1α is a crucial transcription factor associated with cancer metabolism and is regarded as a potent anticancer therapeutic strategy within the hypoxic microenvironment of cancer. In this study, stilbenoid derivatives were designed, synthesized, and assessed for their capacity to inhibit HIF-1α-associated cancer metabolism and evaluated for inhibition of cancer cell viability and HIF activation. Through the structure-activity relationship studies, compound 28e was identified as the most potent derivative. Specifically, under the hypoxic condition, 28e reduced the accumulation of HIF-1α protein and the expression of its target genes related to glucose metabolism without affecting the expression of HIF-1α mRNA. Furthermore, 28e inhibited glucose uptake, glycolytic metabolism, and mitochondrial respiration, decreasing cellular ATP production under hypoxic conditions. In addition, 28e displayed significant anti-tumor effects and effectively suppressed the accumulation of HIF-1α protein in tumor tissue in vivo xenograft model. These findings suggest that our stilbenoid derivatives exert their anticancer effects by targeting HIF-1α-centered cancer metabolism under hypoxic conditions.
- Published
- 2024
- Full Text
- View/download PDF